Progress towards therapies for disease modification in Parkinson's disease

Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Disease—A Pilot Study

(2020) Abhishek G. Sathe et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson’s disease

(2020) Makoto Naoi et al.   JOURNAL OF NEURAL TRANSMISSION

Brain mitochondrial impairment in early‐onset Parkinson's disease with or without PINK1 mutation

(2020) Mario Rango et al.   MOVEMENT DISORDERS

Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology

(2020) Jasper C. A. Broen et al.   Nature Reviews Rheumatology

Disease modification and biomarker development in Parkinson disease

(2020) Alberto J. Espay et al.   NEUROLOGY

Deep phenotyping of peripheral tissue facilitates mechanistic disease stratification in sporadic Parkinson’s disease

(2020) Phillippa J Carling et al.   PROGRESS IN NEUROBIOLOGY

Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations

(2020) Stephen Mullin et al.   JAMA Neurology

Midbrain Organoids: A New Tool to Investigate Parkinson’s Disease

(2020) Lisa Maria Smits et al.   Frontiers in Cell and Developmental Biology

GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop

(2020) Roger A. Barker et al.   Journal of Parkinsons Disease

A New Approach to the Development of Disease‐Modifying Therapies for PD ; Fighting Another Pandemic

(2020) Karl Kieburtz et al.   MOVEMENT DISORDERS

Modulation of the Microbiome in Parkinson’s Disease: Diet, Drug, Stool Transplant, and Beyond

(2020) Ethan G. Brown et al.   Neurotherapeutics

Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice

(2020) Joanna A. Korecka et al.   Molecular Therapy-Nucleic Acids

Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease

(2019) Dilan Athauda et al.   JAMA Neurology

Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson’s Disease

(2019) Liping Zhang et al.   Journal of Parkinsons Disease

Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease

(2019) Constant V.M. Verschuur et al.   NEW ENGLAND JOURNAL OF MEDICINE

Longitudinal analyses of cerebrospinal fluid α‐Synuclein in prodromal and early Parkinson's disease

(2019) Brit Mollenhauer et al.   MOVEMENT DISORDERS

Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism

(2019) Trina Mitchell et al.   HUMAN BRAIN MAPPING

Glucocerebrosidase and its relevance to Parkinson disease

(2019) Jenny Do et al.   Molecular Neurodegeneration

Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

(2019) Mike A Nalls et al.   LANCET NEUROLOGY

Activating Autophagy as a Therapeutic Strategy for Parkinson’s Disease

(2018) Alan J. Fowler et al.   CNS DRUGS

GBA-Associated Parkinson’s Disease and Other Synucleinopathies

(2018) Ziv Gan-Or et al.   Current Neurology and Neuroscience Reports

Inhibition of the hepatic Nlrp3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP/p mouse model of Parkinson’s disease

(2018) Chen Qiao et al.   Journal of Neuroinflammation

β2-adrenoreceptor medications and risk of Parkinson disease

(2018) Susan Searles Nielsen et al.   ANNALS OF NEUROLOGY

Smartphone motor testing to distinguish idiopathic REM sleep behavior disorder, controls, and PD

(2018) Siddharth Arora et al.   NEUROLOGY

LRRK2 activation in idiopathic Parkinson’s disease

(2018) Roberto Di Maio et al.   Science Translational Medicine

The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease

(2018) Noémie Cresto et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2018) E. Ray Dorsey et al.   LANCET NEUROLOGY

Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice

(2018) Richard Gordon et al.   Science Translational Medicine

Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson’s Disease

(2018) Maria Nguyen et al.   TRENDS IN NEUROSCIENCES

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

(2017) Dilan Athauda et al.   LANCET

New perspectives on study designs for evaluating neuroprotection in Parkinson's disease

(2017) Laetitia Thibault et al.   MOVEMENT DISORDERS

Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models

(2017) S. Pablo Sardi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease

(2017) Lena F. Burbulla et al.   SCIENCE

β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease

(2017) Shuchi Mittal et al.   SCIENCE

The Threshold Theory for Parkinson's Disease

(2017) Simone Engelender et al.   TRENDS IN NEUROSCIENCES

Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson’s Disease: Rationale for Clinical Trial, and Current Progress

(2017) Camille B. Carroll et al.   Journal of Parkinsons Disease

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model

(2017) Hien Tran Zhao et al.   Molecular Therapy-Nucleic Acids

Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease

(2017) Antonio Martin-Bastida et al.   Scientific Reports

A New Glucocerebrosidase Chaperone Reduces  -Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism

(2016) E. Aflaki et al.   JOURNAL OF NEUROSCIENCE

Pioglitazone ameliorates the phenotype of a novel Parkinson’s disease mouse model by reducing neuroinflammation

(2016) Milena Pinto et al.   Molecular Neurodegeneration

Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD)

(2016) Caroline H. Williams-Gray et al.   MOVEMENT DISORDERS

First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers

(2016) Dale B. Schenk et al.   MOVEMENT DISORDERS

Technology in Parkinson's disease: Challenges and opportunities

(2016) Alberto J. Espay et al.   MOVEMENT DISORDERS

Development and external validation of a prognostic model in newly diagnosed Parkinson disease

(2016) Daan C. Velseboer et al.   NEUROLOGY

Pathological  -synuclein transmission initiated by binding lymphocyte-activation gene 3

(2016) X. Mao et al.   SCIENCE

Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies

(2016) Fernando Pagan et al.   Journal of Parkinsons Disease

Quantitative Susceptibility Mapping in Parkinson's Disease

(2016) Christian Langkammer et al.   PLoS One

Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease

(2015) Aurelija Jucaite et al.   BRAIN

Glucocerebrosidase activity in Parkinson’s disease with and withoutGBAmutations

(2015) Roy N. Alcalay et al.   BRAIN

Parkinson's disease

(2015) Lorraine V Kalia et al.   LANCET

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial

(2015)   LANCET NEUROLOGY

Development of Passive Immunotherapies for Synucleinopathies

(2015) Ann-Louise Bergström et al.   MOVEMENT DISORDERS

Active immunization therapies for Parkinson's disease and multiple system atrophy

(2015) Achim Schneeberger et al.   MOVEMENT DISORDERS

Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration

(2015) Katrina L. Paumier et al.   NEUROBIOLOGY OF DISEASE

Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons

(2015) Emily M. Rocha et al.   NEUROBIOLOGY OF DISEASE

UDCA exerts beneficial effect on mitochondrial dysfunction inLRRK2G2019Scarriers and in vivo

(2015) Heather Mortiboys et al.   NEUROLOGY

Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease

(2015) Iciar Aviles-Olmos et al.   Journal of Parkinsons Disease

Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells

(2014) Alisdair McNeill et al.   BRAIN

Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease

(2014) Michael A. Schwarzschild et al.   JAMA Neurology

A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease

(2014) et al.   JAMA Neurology

Inhibition of LRRK2 kinase activity stimulates macroautophagy

(2013) Claudia Manzoni et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson’s disease

(2013) Heather Mortiboys et al.   BRAIN

Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of  -synuclein in Parkinson's disease models

(2013) M. L. Hebron et al.   HUMAN MOLECULAR GENETICS

Exenatide and the treatment of patients with Parkinson’s disease

(2013) Iciar Aviles-Olmos et al.   JOURNAL OF CLINICAL INVESTIGATION

α-Synuclein Vaccination Prevents the Accumulation of Parkinson Disease-Like Pathologic Inclusions in Striatum in Association With Regulatory T Cell Recruitment in a Rat Model

(2013) Vanesa Sanchez-Guajardo et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Interplay of LRRK2 with chaperone-mediated autophagy

(2013) Samantha J Orenstein et al.   NATURE NEUROSCIENCE

Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinson’s disease

(2013) Zhongmei Chen et al.   NEUROLOGICAL SCIENCES

Modeling Lewy pathology propagation in Parkinson's disease

(2013) Kelvin C. Luk et al.   PARKINSONISM & RELATED DISORDERS

Triggering of Inflammasome by Aggregated α–Synuclein, an Inflammatory Response in Synucleinopathies

(2013) Gaia Codolo et al.   PLoS One

Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences

(2012) Nicole Exner et al.   EMBO JOURNAL

Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3β signaling pathway

(2012) Li Gong et al.   JOURNAL OF NEUROCHEMISTRY

Design innovations and baseline findings in a long-term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long-Term Study-1

(2012) Jordan J. Elm et al.   MOVEMENT DISORDERS

Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies

(2012) Erwan Bezard et al.   MOVEMENT DISORDERS

Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

(2011) Susan Duty et al.   BRITISH JOURNAL OF PHARMACOLOGY

Neuroinflammation and α-Synuclein Dysfunction Potentiate Each Other, Driving Chronic Progression of Neurodegeneration in a Mouse Model of Parkinson’s Disease

(2011) Hui-Ming Gao et al.   ENVIRONMENTAL HEALTH PERSPECTIVES

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

(2011) Olivier Rascol et al.   LANCET NEUROLOGY

Glia: Initiators and progressors of pathology in Parkinson's disease

(2011) Glenda M. Halliday et al.   MOVEMENT DISORDERS

The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease

(2011) E. Ilijic et al.   NEUROBIOLOGY OF DISEASE

Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death

(2011) Laura A. Volpicelli-Daley et al.   NEURON

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease

(2010) Byoung Dae Lee et al.   NATURE MEDICINE

Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease

(2009) E. Sidransky et al.   NEW ENGLAND JOURNAL OF MEDICINE

The MitoPark Mouse – An animal model of Parkinson's disease with impaired respiratory chain function in dopamine neurons

(2009) Mats I. Ekstrand et al.   PARKINSONISM & RELATED DISORDERS

Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease

(2008) Jeffrey H Kordower et al.   NATURE MEDICINE

Use of antihypertensives and the risk of Parkinson disease

(2008) C. Becker et al.   NEUROLOGY